Exagen Inc
XGN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$183.65M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $183.65 Million |
|---|---|
| Enterprise Value | $186.10 Million |
| Earnings per Share | $-0.93 |
| Beta | 2.12 |
| Outstanding Shares | 24,164,569 |
Return
| Return on Equity | -154.90% |
|---|---|
| Return on Assets | -36.44% |
| Return on Invested Capital | -26.83% |
Valuation & Multiples
| P/E Ratio | -10.48 |
|---|---|
| PEG | 37.41 |
| Price to Sales | 3.8 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.62 |
| Enterprise Value to EBIT | -18.03 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 2.21 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 3, 2026
EPS Estimate
$-0.19
Consensus analyst estimateRevenue Estimate
$18.34 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 32.89% |
|---|---|
| Total Invested | $878▼ 100.00% |
| Investors Holding | 2▼ 55.00% |
About Exagen Inc
182 employees
CEO: Fortunato Rocca
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and i...